This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection
Osteopontin (OPN) influences metastatic behavior of tumors through binding to CD44v6 and integrin. The authors in this study assessed OPN and CD44v6 expression in 159 NSCLC pts and evaluated survival. The combination of markers stratified overall and disease-free survival, especially in stage I pts. Overall survival for [OPN- AND CD44v6-] pts was 64.4%, for [OPN+ OR CD44v6+] was 49.1%, and for [OPN+ AND CD44v6+] was 16.4%.